Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beyond Air (NASDAQ: XAIR) said Steve Lisi, Chairman & CEO, will participate in two investor conferences in early February 2026: the Noble Capital Markets Emerging Growth Virtual Equity Conference (Feb 4–5) and the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Feb 9–11) in Snowbird, UT.
The Noble event includes a corporate presentation on Feb 5 at 2:00 PM ET plus one-on-one meetings; the presentation will be webcast live and archived on the company website for 90 days following the event. BTIG participation is scheduled as one-on-one meetings.
Details
News Market Reaction – XAIR
On Jan 28, the first trading day after this news, XAIR closed 5.93% below the previous close.
Data tracked by StockTitan Argus for the Jan 28 session.
Key Figures
- BTIG conference edition
- 13th Annual
- BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- BTIG conference dates
- February 9–11
- BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2026
- Noble conference dates
- February 4–5
- Noble Capital Markets Emerging Growth Virtual Equity Conference 2026
- Noble presentation time
- February 5 at 2:00pm ET
- Scheduled Beyond Air corporate presentation
- Webcast archive period
- 90 days
- Duration webcast replay will be available on company website
Historical Context
-
Set date for Q3 FY2026 results call and webcast in mid-February.
-
Announced $5.0M at-the-market private placement with new warrants issued.
-
Agreed to sell 85% of NeuroNOS for equity, cash, and milestones.
-
Appointed new CFO with option grant and prior controller resuming role.
-
Signed new LungFit PH distribution deals expanding to 39 countries.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Capital Markets Emerging Growth Virtual Equity Conference being held February 4th to 5th.
| BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference | ||
| Format: | One-on-one meetings | |
| Conference Dates: | February 9thto 11th | |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air | |
| Noble Capital Markets Emerging Growth Virtual Equity Conference | ||
| Format: | Corporate presentation and one-on-one meetings | |
| Presentation Date: | Thursday, February 5that 2:00pm ET | |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air | |
| Live Webcast link: | Attendees interested in viewing the live presentation can register for this event at no cost, here: Virtual Equity Conference Registration. An archive of the webcast will be available at https://www.beyondair.net/news-events/eventsfor 90 days following the event | |
If you are interested in requesting a one-on-one meeting at either of the conferences, please contact your respective bank representative to schedule accordingly.
About Beyond Air®, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.
CONTACTS:
Investor Relations
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.